September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016

Therapeutic potential of topical ROCK inhibitor Ripasudil (K-115) in choroidal neovascularization
Author Affiliations & Notes
  • Muneo Yamaguchi
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Shintaro Nakao
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Yoshihiro Kaizu
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Yoshiyuki Kobayashi
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Takahito Nakama
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Shigeo Yoshida
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Yuji Oshima
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Tatsuro Ishibashi
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Koh-hei Sonoda
    Dept of Ophthalmology Sch of Med, Kyushu University, Fukuoka-shi, Fukuoka, Japan
  • Yoshio Kaneko
    Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Noguchicho, Higashimurayama, Tokyo, Japan
  • Tomoyuki Isobe
    Tokyo New Drug Research Laboratories, Kowa Company, Ltd., Noguchicho, Higashimurayama, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Muneo Yamaguchi, None; Shintaro Nakao, Kowa company (P); Yoshihiro Kaizu, None; Yoshiyuki Kobayashi, None; Takahito Nakama, None; Shigeo Yoshida, None; Yuji Oshima, None; Tatsuro Ishibashi, Kowa company (P); Koh-hei Sonoda, None; Yoshio Kaneko, Kowa company (E); Tomoyuki Isobe, Kowa company (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1109. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Muneo Yamaguchi, Shintaro Nakao, Yoshihiro Kaizu, Yoshiyuki Kobayashi, Takahito Nakama, Shigeo Yoshida, Yuji Oshima, Tatsuro Ishibashi, Koh-hei Sonoda, Yoshio Kaneko, Tomoyuki Isobe;
      Therapeutic potential of topical ROCK inhibitor Ripasudil (K-115) in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1109.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose :
Anti-VEGF therapy is widely used for age related macular degeneration in clinic. However, frequent intravitreal injections are needed for maximum effect. In this study, we investigated the therapeutic potential of a topical Rho-associated protein kinase (ROCK) inhibitor, ripasudil (K-115), in pathological choroidal neovascularization (CNV).

Methods :
C57BL/6J mice underwent retinal laser photocoagulation to induce CNV. Experiment 1. Ripasudil (3 or 30 µmol/L) as well as aflibercept were treated intravitreally every 3 days after laser injury. Experiment 2. A physiological saline solution, a 0.4% ripasudil ophthalmic solution, or a 0.8% ripasudil ophthalmic solution was applied topically to both eyes of the animals 3 times daily for 7 days. The volume of CNV was quantified with choroidal flat mounts stained by lectin.

Results :
1. Intravitreal ripasudil treatment could reduce the volumes of CNV significantly at the similar level of aflibercept treatment (49% reduction from baseline at 3 µmol/L ripasudil; p<0.01 vs control, 56% reduction at 30 µmol/L ripasudil; p<0.01 vs control). 2. The volumes of CNV at day 7 after laser injury was significantly reduced in a 0.8% ripasudil ophthalmic solution groups (32% reduction from baseline at 0.4% ripasudil; p=0.06 vs saline, 41% reduction at 0.8% K-115; p=0.03 vs saline).

Conclusions :
Topical as well as intravitreal ripasudil treatment has the potential to become a novel therapeutic strategy in the treatment of choroidal neovascularization.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×